Drug Prices
As urged by the AHA, the Health Resources and Services Administration today announced that it expects to publish online by April 1 drug ceiling prices under the 340B Drug Pricing Program.
The Campaign for Sustainable Rx Pricing, of which the AHA is a founding member, yesterday released a new ad urging Congress to keep its commitment to lower drug prices.
Special Bulletin on CMS’s Nov. 26 proposed rule aimed at lowering drug prices for beneficiaries enrolled in Medicare Advantage and Part D programs.
The Centers for Medicare & Medicaid Services late today issued a proposed rule that would provide Medicare Advantage and Part D plans more tools to negotiate lower drug prices.
The AHA today urged the Health Resources and Services Administration to meet the Jan. 1 effective date it has proposed for its final rule on drug ceiling prices and civil monetary penalties for manufacturers under the 340B Drug Pricing Program.
The AHA urges the Health Resources and Services Administration to meet the Jan. 1 effective date it has proposed for its final rule on drug ceiling prices and civil monetary penalties for manufacturers under the 340B Drug Pricing Program.
Seventeen organizations, including the AHA, today urged Congress to resist any attempts from the pharmaceutical industry to undo during the lame duck session provisions included in the Bipartisan Budget Act to make prescription drugs more affordable for seniors.
On October 25, the Centers for Medicare & Medicaid Services issued an advance notice of proposed rulemaking to solicit public comments on potential options for testing a new model for paying for prescription drugs under Medicare Part B provided in physician offices, hospital outpatient…
The Centers for Medicare & Medicaid Services today issued an advance notice of proposed rulemaking seeking comments through Dec. 31 on potential options the agency may consider for testing changes to payment for certain separately payable Part B drugs and biologicals.